ARTICLES BY RONALD A. RADER
-
The “New Normal”: Changing Perceptions on Bioprocess Intensification and Continuous Bioprocessing3/1/2021
Process intensification and continuous bioprocessing are concepts with inconsistent definitions. What's included often varies greatly and, in some ways, has become more about aspirational goal-setting than actual innovation adoption. Here, BioPlan Associates assesses the changing perspectives of 122 bioprocess decision-makers.
-
Bioprocessing Year In Review: 11 Key Trends Accelerated By COVID-1912/11/2020
Despite the morbidity, deaths, and terrible societal disruptions associated with the COVID-19 pandemic, 2020 will have created something of a positive outcome for the bioprocessing sector.
-
COVID-19's Impact On Bioprocessing: Insights From Industry Leaders8/5/2020
We interviewed 26 biopharma senior executives regarding how they are handling the crisis and its long-term impact on their operations. We found the pandemic has begun to catalyze and accelerate a number of significant changes, including many preexisting trends.
-
Biosimilar Pipeline Experiencing 12% Annual Growth: A Progress Update3/26/2020
This article compares aspects of the biosimilar development pipeline and related market evolution since 2013, including what has and hasn’t changed.
-
Biosimilars Pipeline Shows Remarkable, Sustained Growth3/7/2019
The biosimilars pipeline is progressing rapidly and continues to grow, with more products and more organizations involved. This article reviews the current biosimilars development pipeline and progress.
-
Top Trends In The Biopharmaceutical Industry And Bioprocessing For 201912/18/2018
This article presents trends and findings from a survey and study of 222 responsible individuals at biopharmaceutical manufacturers and CMOs in 22 countries, as well as over 130 direct suppliers of materials, services, and equipment to this industry.
-
Biosimilars Pipeline Analysis: Many Products, More Competition Coming7/26/2016
Our discussion of biosimilars in this article will center on developed-market GMP biosimilars. In the European market alone, biosimilars already are a multibillion-dollar business, and one that is rapidly growing.